A Phase II Randomized Study of Atezolizumab Plus Multi-Kinase Inhibitor Versus Multi-Kinase Inhibitor Alone in Subjects with Unresectable, Advanced Hepatocellular Carcinoma Who Previously Received Atezolizumab Plus Bevacizumab

Protocol No

The purpose of this research study is to find out what effects, good and/or bad, Atezolizumab and Cabozantinib or Lenvatinib has on you and your liver cancer.

Atezolizumab is approved by the FDA for the treatment of many types of cancer, but its use in this study is investigational. Cabozantinib and Lenvatinib are approved by the FDA for the treatment of advanced unresectable liver cancer for patients who have previously received Atezolizumab plus Bevacizumab, but its use in combination with Atezolizumab in this study is investigational.

Your condition may get better, but it could stay the same or even get worse. We hope the information from this study will help us develop a better treatment for liver cancer in the future.

Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
Participating Institutions
Froedtert Hospital